Mometasone Furoate Improves Total Ocular Symptom Score in Patients With Allergic Rhinitis

2007 ◽  
Vol 119 (1) ◽  
pp. S61 ◽  
Author(s):  
J. Hébert ◽  
M. Danzig ◽  
D. Gates
Keyword(s):  
Allergic Rhinitis ◽  
Symptom Score ◽  
Ocular Symptom ◽  
Mometasone Furoate

scholarly journals Therapeutic comparability of Dezrinit and Nazonex® in control of symptoms of allergic rhinitis. The results of a multicenter, open, randomized, comparative study in parallel groups

2016 ◽  
Vol 13 (3) ◽  
pp. 65-74
Author(s):  
N I Ilina ◽  
T G Fedoskova ◽  
N G Astafieva ◽  
L A Gorychkina ◽  
A S Edin ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Symptom Score ◽  
Nasal Spray ◽  
Nasal Symptom ◽  
Ocular Symptom ◽  
Mometasone Furoate ◽  
Total Nasal Symptom Score ◽  
Metered Dose ◽  
Comparison Groups ◽  
Receive Treatment

Background. To study efficacy and safety of Dezrinit (mometasone furoate, metered dose nasal spray, 200 pg/day) in comparison with Nasonex® (mometasone furoate, metered dose nasal spray, 200 pg/day) upon administration for 14 days in adult patients with seasonal allergic rhinitis. Materials and methods. A total of 141 patients were enrolled into the study at 8 study centers in the RF, of which 134 patients were randomized: 67 patients into the experimental group (Dezrinit) and 67 patients into the comparison group (Nasonex®). patients were randomized to receive treatment either with Dezrinit or Nasonex®. Efficacy was assessed based on reflective Total Nasal Symptom Score (rTNSS) and instantaneous Total Nasal Symptom Score (iTNSS); reflective Total Ocular Symptom Score (rTOSS) and instantaneous Total Ocular Symptom Score (iTOSS). Overall proportion of patients who responded to treatment was evaluated according to overall assessment of treatment efficacy both by a patient and by an investigator. AEs were reported for safety assessment. Results. After 14 days of treatment a marked improvement of symptoms was observed in both groups based on all assessed scores. Mean change (SD) in rTNSS from baseline was -11,91 (4,625) scores and -11,64 (4,58) scores in the experimental and comparison groups, respectively (within group differences, p

Effectiveness of Oral Antihistamines and Intranasal Steroid Spray in relieving Ocular Symptoms in Allergic Rhinitis using Total Ocular Symptom Score

2016 ◽  
Vol 8 (2) ◽  
pp. 45-50
Author(s):  
Namit K Singh ◽  
Prakash S Nagpure ◽  
Manish K Yadav ◽  
Shushil Chavan ◽  
Shraddha Manpe ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Symptom Score ◽  
Controlled Trial ◽  
Statistical Significance ◽  
Ocular Symptom ◽  
Mometasone Furoate ◽  
Chi Square ◽  
Ocular Symptoms ◽  
Intranasal Corticosteroid Spray ◽  
Group B

ABSTRACT Ocular symptoms in allergic rhinitis are often overlooked, but they have a significant impact on the quality of life of an individual. Materials and methods A randomized controlled trial was conducted from August 2012 to July 2013; a total of 153 cases were considered and divided into two groups. Group A received levocetirizine, and group B received mometasone furoate nasal spray. Aims and objectives The aims and objectives of this study were to determine the total ocular symptom score (TOSS) according to the severity of allergic rhinitis, determine the TOSS before medication, and determine the effectiveness of antihistamines (levocetirizine) and intranasal corticosteroid spray (mometasone furoate). Results The results indicate average TOSS to be in intermittent mild (51.32), intermittent moderate to severe (55.86), persistent mild (44.50), and persistent moderate to severe (52.02). Chi-square test to compare the relief between groups A and B did not show any statistical significance after 1st (p = 0.8951) and 4th weeks (p = 0.9758) of follow-up. How to cite this article Singh NK, Nagpure PS, Yadav MK, Chavan S, Manpe S, Ganeshkar R. Effectiveness of Oral Antihistamines and Intranasal Steroid Spray in relieving Ocular Symptoms in Allergic Rhinitis using Total Ocular Symptom Score. Int J Otorhinolaryngol Clin 2016;8(2):45-50.

A randomized study comparing the efficacy of mometasone furoate and fluticasone furoate on the ocular and nasal symptoms of allergic rhinitis

2017 ◽  
Vol 3 (4) ◽  
pp. 918
Author(s):  
Satvinder Singh Bakshi ◽  
Surianarayanan Gopalakrishnan ◽  
Nirmal Coumare V.
Keyword(s):  
Allergic Rhinitis ◽  
Symptom Score ◽  
Nasal Spray ◽  
Randomized Study ◽  
Nasal Symptom ◽  
Mometasone Furoate ◽  
Fluticasone Furoate ◽  
Ocular Symptoms ◽  
Nasal Symptoms ◽  
Group B

<p class="abstract"><strong>Background:</strong> Ocular symptoms like itching, redness and congestion are common in patients with allergic rhinitis. These symptoms affect the quality of life and increase the burden on the healthcare cost. Intranasal steroids are effective in reducing the nasal and ocular symptoms of allergic rhinitis. We aim to compare the efficacy of mometasone furoate nasal spray and fluticasone furoate nasal spray in reducing the nasal and ocular symptoms of allergic rhinitis.</p><p class="abstract"><strong>Methods:</strong> 90 patients with perennial allergic rhinitis and ocular symptoms were randomly divided into 2 groups. Group A (n=46) received 200 µg of mometasone furoate nasal spray once daily and Group B (n=44) received 110 µg of fluticasone furoate nasal spray daily. The patients were assessed by total ocular symptom score [TOSS] and total nasal symptom score [TNSS] at 2, 6 and 12 weeks interval.  </p><p class="abstract"><strong>Results:</strong> There was a statistically significant reduction in both the groups in respect to the TOSS and TNSS scores. However the improvement in the TOSS score in the fluticasone furoate group was more than the mometasone furoate group by 6 weeks (p=0.0009), which continued till the 12 weeks (p=0.045).</p><p><strong>Conclusions:</strong> Fluticasone furoate is more effective than mometasone furoate in managing the ocular and nasal symptoms of allergic rhinitis. </p>

scholarly journals Comparison of Outcomes Between Mometasone Furoate Intranasal Spray and Oral Montelukast in Patients with Allergic Rhinitis

2020 ◽  
Vol 18 (2) ◽  
pp. 268-270
Author(s):  
Sushma Bhattachan ◽  
Yogesh Neupane ◽  
Bibhu Pradhan ◽  
Naramaya Thapa
Keyword(s):  
Allergic Rhinitis ◽  
Symptom Score ◽  
Nasal Symptom ◽  
Mometasone Furoate ◽  
Total Ige ◽  
Total Nasal Symptom Score ◽  
Medication Score ◽  
The Mean ◽  
Serum Total Ige ◽  
Intranasal Spray

Background: Allergic rhinitis is a common ailment with rising trend and worldwide prevalence of some 400 million. Methods: This prospective randomized crosssectional study was done at the Department of Otorhinolaryngology and Head and Neck Surgery, Tribhuvan University, Teaching Hospital, Kathmandu, Nepal from June 2016 to August 2017. They were randomly assigned to two groups by lottery method. Group A received mometasone furoate intranasal spray and Group B received oral montelukast for a total duration of one month. Prior to starting medication and one month after medications, total nasal symptom score was documented. Statistical analysis was done using SPSS version 18.Results: Total of 126 patients between 16 to 52 years were enrolled in the study. The mean duration of symptoms was 3.93 years. The mean value of serum total IgE was 833.49 IU/ml. The mean pre and post medication score for mometasone furoate intranasal spray group was 16.32 and 5.44 respectively, which was significant. Similarly, the mean pre and post medication score for oral montelukast group was 15.24 and 7.87 respectively which was also found to be significant. Comparing the means of scores for both the groups, mometasone furoate was found to be more effective than oral montelukast.Conclusions: Both mometasone furoate intranasal spray and oral montelukast were effective in the treatment of patient with allergic rhinitis. Oral montelukast can therefore be used as a first line treatment for patients with allergic rhinitis. Keywords: Allergic rhinitis; mometasone furoate intranasal spray; montelukast; serum total IgE; total nasal symptom score.

S100 – Mometasone Furoate Reduces Ocular Symptoms of Seasonal AR

2008 ◽  
Vol 139 (2_suppl) ◽  
pp. P111-P111
Author(s):  
Bruce Prenner ◽  
Tulin Shekar ◽  
Ariel Teper
Keyword(s):  
Symptom Score ◽  
Nasal Symptom ◽  
Ocular Symptom ◽  
Mometasone Furoate ◽  
Phase Iii ◽  
Double Blind ◽  
Daily Diaries ◽  
Ocular Symptoms ◽  
Symptom Scores ◽  
Multi Center Study

Objectives To demonstrate clinical efficacy in reducing the ocular symptoms of SAR using mometasone furoate nasal spray (MFNS). Methods A phase III, double-blind, randomized, placebo-controlled, multi-center study compared the efficacy of MFNS 200 mcg QD, dosed in the morning (AM), for treatment of ocular symptoms associated with SAR. Subjects were at least 12 years old with at least a 2-year history of SAR. In daily diaries, subjects evaluated AM ocular symptom severity on a scale of 0 (none) to 3 (severe) on treatment Days 1 to 15. Co-primary endpoints included change from baseline in average instantaneous (AM) total nasal symptom score (sum of individual nasal symptom scores for congestion, rhinorrhea, sneezing, and itching) and instantaneous (AM) total ocular symptom score (iTOSS) (sum of individual eye symptom scores for itching/burning, tearing/watering, redness), Days 2 to 15. Results Subjects (429) with similar baseline characteristics and moderate-to-severe ocular symptoms received MFNS 200 mcg QD or placebo. MFNS 200 mcg QD demonstrated superiority over placebo in least squares mean changes from baseline in subject-rated, average AM iTOSS from Day 2 to 15 (−1.71 [−25.1%] and −1.37 [−20.1%], respectively; P equal to 0.026). MFNS was well tolerated. Conclusions MFNS 200 mcg QD demonstrated statistically significant improvements in AM iTOSS associated with SAR. These are the first prospective results demonstrating that MFNS significantly reduces ocular symptoms in subjects with SAR.

Sign in / Sign up

Export Citation Format

Share Document